Pfizer (NYSE:PFE) Releases FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.800-3.000 for the period, compared to the consensus estimate of 2.970. The company issued revenue guidance of $60.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.7 billion.

Pfizer Stock Up 0.7%

Shares of Pfizer stock traded up $0.18 during trading on Wednesday, hitting $25.59. The company’s stock had a trading volume of 11,383,232 shares, compared to its average volume of 42,182,402. The company has a fifty day simple moving average of $25.02 and a two-hundred day simple moving average of $26.16. The company has a market capitalization of $145.85 billion, a PE ratio of 19.53 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer has a 52 week low of $23.58 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PFE shares. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. UBS Group restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported second-quarter adjusted earnings of $0.77 per share, above the $0.68 analyst consensus, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Revenue increased 2.6% year over year. Pfizer beats quarterly profit estimates on strong demand for Eliquis
• Positive Sentiment: The company raised the low end and midpoint of its 2026 revenue forecast to $60.5 billion-$62.5 billion, up from $59.5 billion-$62.5 billion, as Eliquis, oncology medicines, and launched and acquired products offset weaker COVID demand. Pfizer tops quarterly estimates, hikes low end of revenue guidance
• Positive Sentiment: Management plans approximately $2.5 billion in additional cost reductions by 2029, supporting margins and cash generation. Pfizer also reaffirmed adjusted 2026 EPS guidance of $2.80-$3.00, despite an estimated $0.10 per-share impact from its Innovent Biologics transaction. Pfizer Q2 earnings call highlights
• Positive Sentiment: Pfizer reported positive Phase 3 data for LITFULO in vitiligo, adding a potential new use for the drug and another pipeline catalyst. The company is also advancing an obesity-treatment candidate that management believes could deliver competitive weight-loss results. Pfizer reports positive Phase 3 LITFULO data
• Neutral Sentiment: Pfizer’s longer-term recovery depends on replacing revenue from mature products and rebuilding growth beyond 2028; management emphasized oncology, newly launched medicines, business-development activity, and cost discipline as key drivers.
• Negative Sentiment: COVID vaccine and antiviral sales continue to decline sharply, partly limiting the benefit of the broader portfolio’s growth. Pfizer also swung to a quarterly loss under generally accepted accounting principles, which may temper enthusiasm despite the adjusted earnings beat. Pfizer ducks continued COVID fallout

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp boosted its position in Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Morgan Stanley raised its stake in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,540,119 shares of the biopharmaceutical company’s stock valued at $1,258,449,000 after buying an additional 410,082 shares in the last quarter. Finally, Amundi raised its position in Pfizer by 13.4% during the fourth quarter. Amundi now owns 47,063,380 shares of the biopharmaceutical company’s stock valued at $1,171,879,000 after acquiring an additional 5,572,451 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.